Key result
The IRS1 rs1801276 'GG+GC' genotype was associated with a 40% lower risk of nonalcoholic fatty liver disease compared to the 'CC' genotype (OR 0.60, 95% CI 0.45-0.93).
Why the study?
The study was designed to investigate the possible effect of the insulin receptor substrate 1 (IRS1) gene rs1801276 polymorphism on the risk of NAFLD.
Is the IRS1 gene rs1801276 polymorphism associated with the risk of nonalcoholic fatty liver disease?
Case-Control (n=250)
Single-blind
Yes
Is the IRS1 gene rs1801276 polymorphism associated with the risk of nonalcoholic fatty liver disease?
Odds Ratio: 0.6 (95% CI 0.45–0.93)
Absolute Event Rate: 18.7% vs 30.7%
p-value: p=0.041
The IRS1 gene rs1801276 polymorphism appears to be associated with the risk of developing nonalcoholic fatty liver disease.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Asadi et al. (2024) conducted a case-control in Nonalcoholic fatty liver disease (n=250). IRS1 gene rs1801276 'GG+GC' genotype vs. IRS1 gene rs1801276 'CC' genotype was evaluated on Presence of nonalcoholic fatty liver disease (NAFLD) (OR 0.60, 95% CI 0.45-0.93, p=0.041). The IRS1 rs1801276 'GG+GC' genotype was associated with a 40% lower risk of nonalcoholic fatty liver disease compared to the 'CC' genotype (OR 0.60, 95% CI 0.45-0.93).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: